The latest call
FetchingNuvation Bio Inc. reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
$3.99-1.5%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Just reported
From Nuvation Bio Inc.'s results release of November 4, 2026; its quarterly report has since been filed.
Actual
$45M
+243% y/y
+42% q/q
Guided
—
No guide given
Actual
-$0.12
Guided
—
No guide given
Actual
-$42.2M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $45M | $13.1M | +242.61% |
| Profit | -$41.9M | -$55.8M | +24.90% |
| Profit per share | -$0.12 | -$0.16 | +25.00% |
| Free Cash Flow | -$40.1M | -$52.9M | +24.11% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Nuvation Bio Inc. reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Just over one year after launch, IBTROZI was established as the market leader in advanced ROS1+ NSCLC, for both new patient starts and active patients across all lines of therapy combined, based on IQVIA claims data,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Glioma Gliomas are the most common type of brain cancer in adults worldwide. In the U.S., nearly 2,500 people are diagnosed with IDH -mutant gliomas each year, of which more than 95% harbor a mutation in the IDH1 gene. Most patients are diagnosed in their 30s and 40s. While patients with IDH1 mutations generally have longer survival times than those with wild-type IDH1 , gliomas are not currently curable and prognosis worsens for those with high-risk features, including high-grade tumors.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Nuvation Bio Inc.’s Item 2.02 8-K filed November 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.